Home > Insider Trading > Filing (0001209191-12-039313)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1544116	Durata Therapeutics Inc.	DRTX	Pharmaceutical Preparations (2834)	871247903

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1419148	Canaan Viii Lp	C/O Canaan Partners, 285 Riverside Avenue, Suite 250 Westport CT 06880	Yes	No	Yes	No
1552200	Canaan Partners Viii Llc	C/O Canaan Partners, 285 Riverside Avenue, Suite 250 Westport CT 06880	Yes	No	Yes	No
1555070	Canaan Management, Inc.	C/O Canaan Partners, 285 Riverside Avenue, Suite 250 Westport CT 06880	Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-07-24	1,346,475	$0.00	1,346,475	No	4	C	Direct
Common Stock	Acquisiton	2012-07-24	555,555	$9.00	1,902,030	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2012-07-24	10,771,804	$0.00	1,346,475	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2012-02-28	6,250	$0.00	6,250	$2.08

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
6,250		2022-02-27	No	4	A	Indirect

Footnotes

The Series A Preferred Stock has no expiration date and each share of Series A Preferred Stock converted automatically into 0.125 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
Shares held directly by Canaan VIII L.P ("Canaan L.P."). Canaan Partners VIII LLC ("Canaan LLC"), the general partner of Canaan L.P., may be deemed to share voting, investment and dispositive power with respect to shares held by Canaan L.P., but disclaims beneficial ownership of the securities held by Canaan L.P. except to the extent of any pecuniary interest therein.
Mr. Brenton K. Ahrens, a member and manager of Canaan LLC and a vice-president of Canaan Management, Inc. ("Canaan Management", and together with Canaan L.P. and Canaan LLC, the "Canaan Entities"), serves as the representative of the Canaan Entities on the Issuer's board of directors.
This option was granted on February 28, 2012 to Mr. Ahrens with respect to 6,250 shares of common stock, vesting in 36 substantially equal monthly installments over a three year period, the first installment of which vested on March 28, 2012.
Mr. Ahrens, pursuant to arrangements with Canaan LLC and Canaan Management, is contractually obligated to remit the value of any remuneration received for service as a director. Each of the Canaan Entities disclaims beneficial ownership in the stock options held by Mr. Ahrens, except to the extent, if any, of its pecuniary interest therein.